	US 12,304,967 B2
	Fusion protein and use thereof
Ming Lv, Hangzhou (CN); Xiaoran Ding, Hangzhou (CN); Shiwei Miao, Hangzhou (CN); Bin Tan, Hangzhou (CN); and Xuegong Wang, Hangzhou (CN)
Assigned to HANGZHOU SUMGEN BIOTECH CO., LTD., Hangzhou (CN); and SUMGEN MAB (BEIJING) BIOTECH CO., LTD., Beijing (CN)
Appl. No. 17/293,729
Filed by HANGZHOU SUMGEN BIOTECH CO., LTD., Hangzhou (CN); and SUMGEN MAB (BEIJING) BIOTECH CO., LTD., Beijing (CN)
PCT Filed Nov. 13, 2019, PCT No. PCT/CN2019/117856 § 371(c)(1), (2) Date May 13, 2021, PCT Pub. No. WO2020/098672, PCT Pub. Date May 22, 2020.
Claims priority of application No. 201811356690.9 (CN), filed on Nov. 14, 2018.
Prior Publication US 2021/0317230 A1, Oct. 14, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/30 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01)

CPC C07K 16/30 (2013.01) [A61P 35/00 (2018.01); C07K 16/2803 (2013.01); C07K 16/2863 (2013.01); C07K 16/2896 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/565 (2013.01); C07K 2319/30 (2013.01)]

16 Claims

1. A fusion protein, comprising:

a first binding domain that specifically binds a tumor-associated antigen; and

a second binding domain that specifically binds a CD47 protein;

wherein said second binding domain comprises a mutant of a human SIRPα variant 1 domain, wherein said mutant of the human SIRPα variant 1 domain comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 52, 53, 60, 61, 62 or 64.